Rena Conti

Personal Details

First Name:	Rena
Middle Name:
Last Name:	Conti
Suffix:
RePEc Short-ID:	pco1176
Terminal Degree:	2006 (from RePEc Genealogy)

Affiliation

Department of Markets, Public Policy and Law
Questrom School of Business
Boston University

Boston, Massachusetts (United States)
https://www.bu.edu/questrom/faculty/academic-departments/markets-public-policy-law/
RePEc:edi:mppbuus (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson, 2020. "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US," PharmacoEconomics, Springer, vol. 38(10), pages 1115-1121, October.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 12th October 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-10-12 11:00:03

Working papers

1. Chi Heem Wong & Dexin Li & Nina Wang & Jonathan Gruber & Rena M. Conti & Andrew W. Lo, 2021. "Estimating the Financial Impact of Gene Therapy in the U.S," NBER Working Papers 28628, National Bureau of Economic Research, Inc.

   Cited by:

   1. Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).

2. Rena M. Conti & Jonathan Gruber & Daniel A. Ollendorf & Peter J. Neumann, 2020. "Valuing Rare Pediatric Drugs: An Economics Perspective," NBER Working Papers 27978, National Bureau of Economic Research, Inc.

   Cited by:

   1. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
   2. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
      • Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.

3. Neriman Beste Kaygisiz & Yashna Shivdasani & Rena M. Conti & Ernst R. Berndt, 2019. "The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications," NBER Working Papers 26524, National Bureau of Economic Research, Inc.

   Cited by:

   1. Santini, Alberto, 2021. "Optimising the assignment of swabs and reagent for PCR testing during a viral epidemic," Omega, Elsevier, vol. 102(C).

4. Rena M. Conti & Ernst R. Berndt, 2019. "Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets," NBER Working Papers 26194, National Bureau of Economic Research, Inc.

   Cited by:

   1. Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth, 2022. "Effect of Competition on Generic Drug Prices," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 243-253, March.
   2. Nguyen Xuan Nguyen & Steven Sheingold & Arielle Bosworth & Rachael Zuckerman & Thomas Buchmueller, 2025. "Effect of Market Entry on Generic Drug Prices: Medicare Data 2007-2022," International Journal of Research and Innovation in Social Science, International Journal of Research and Innovation in Social Science (IJRISS), vol. 9(1), pages 1485-1496, January.

5. Paolo M. Adajar & Ernst R. Berndt & Rena M. Conti, 2019. "The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration," NBER Working Papers 26512, National Bureau of Economic Research, Inc.

   Cited by:

   1. Sündal, Doğuhan, 2024. "Relative size distribution of business firms—A QRSE approach," Economic Modelling, Elsevier, vol. 140(C).
   2. N. M. Rozanova, 2021. "Methodological Issues of Modern Competition Policy," Studies on Russian Economic Development, Springer, vol. 32(5), pages 492-498, September.

6. Ernst R. Berndt & Rena M. Conti & Stephen J. Murphy, 2017. "The Generic Drug User Fee Amendments: An Economic Perspective," NBER Working Papers 23642, National Bureau of Economic Research, Inc.

   Cited by:

   1. Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth, 2022. "Effect of Competition on Generic Drug Prices," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 243-253, March.
   2. Ernst R. Berndt & Rena M. Conti & Stephen J. Murphy, 2017. "The Landscape of US Generic Prescription Drug Markets, 2004-2016," NBER Working Papers 23640, National Bureau of Economic Research, Inc.

7. Ernst R. Berndt & Rena M. Conti & Stephen J. Murphy, 2017. "The Landscape of US Generic Prescription Drug Markets, 2004-2016," NBER Working Papers 23640, National Bureau of Economic Research, Inc.

   Cited by:

   1. Alice M. Ellyson & Anirban Basu, 2018. "The New Prescription Drug Paradox: Pipeline Pressure and Rising Prices," NBER Working Papers 24387, National Bureau of Economic Research, Inc.
   2. Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth, 2022. "Effect of Competition on Generic Drug Prices," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 243-253, March.
   3. Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2018. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 115-157, National Bureau of Economic Research, Inc.
      • Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2017. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Working Papers 24026, National Bureau of Economic Research, Inc.
   4. Atanu Saha & Yong Xu, 2023. "Estimating Brand Drugs’ Payoff from Pay-for-Delay Deals," Journal of Industry, Competition and Trade, Springer, vol. 23(1), pages 81-99, June.
   5. Robert Clark & Christopher Anthony Fabiilli & Laura Lasio, 2021. "Collusion in the US Generic Drug Industry," Working Paper 1474, Economics Department, Queen's University.
      • Clark, Robert & Fabiilli, Christopher & Lasio, Laura, 2022. "Collusion in the US generic drug industry," International Journal of Industrial Organization, Elsevier, vol. 85(C).
   6. Granlund, David & Rudholm, Niklas, 2023. "Calculating the probability of collusion based on observed price patterns," Umeå Economic Studies 1014, Umeå University, Department of Economics, revised 13 Oct 2023.
   7. Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
   8. Jun Li & Di (Andrew) Wu, 2022. "The Price Effect of Drug Price Ceilings: Intended and Unintended Consequences," Management Science, INFORMS, vol. 68(8), pages 5758-5777, August.
   9. Leemore Dafny & Kate Ho & Edward Kong, 2024. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?," American Economic Journal: Economic Policy, American Economic Association, vol. 16(3), pages 314-346, August.
   10. Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
   11. Antonio J. Trujillo & Jose C. Gutierrez & Emmanuel E. Garcia Morales & Mariana Socal & Jeromie Ballreich & Gerard Anderson, 2022. "Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?," Health Economics Review, Springer, vol. 12(1), pages 1-12, December.

8. David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
   • David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," Journal of Economic Perspectives, American Economic Association, vol. 29(1), pages 139-162, Winter.

   Cited by:

   1. Kyle, Margaret & Dubois, Pierre, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality," CEPR Discussion Papers 11487, C.E.P.R. Discussion Papers.
   2. Timothy L. Hamilton & Erik B. Johnson, 2023. "The amenity value of natural views," Real Estate Economics, American Real Estate and Urban Economics Association, vol. 51(5), pages 1079-1107, September.
   3. Massimo FLORIO & Francesco GIFFONI, 2019. "L’impatto sociale della produzione di scienza su larga scala: come governarlo?," Departmental Working Papers 2019-05, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
   4. Shepard, Mark & Baicker, Katherine & Skinner, Jonathan, 2019. "Does One Medicare Fit All? The Economics of Uniform Health Insurance Benefits," Working Paper Series rwp19-036, Harvard University, John F. Kennedy School of Government.
      • Mark Shepard & Katherine Baicker & Jonathan Skinner, 2020. "Does One Medicare Fit All? The Economics of Uniform Health Insurance Benefits," Tax Policy and the Economy, University of Chicago Press, vol. 34(1), pages 1-41.
      • Mark Shepard & Katherine Baicker & Jonathan S. Skinner, 2019. "Does One Medicare Fit All? The Economics of Uniform Health Insurance Benefits," NBER Working Papers 26472, National Bureau of Economic Research, Inc.
      • Mark Shepard & Katherine Baicker & Jonathan Skinner, 2019. "Does One Medicare Fit All? The Economics of Uniform Health Insurance Benefits," NBER Chapters, in: Tax Policy and the Economy, Volume 34, pages 1-41, National Bureau of Economic Research, Inc.
   5. Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Other publications TiSEM 700b2f3e-d1c8-4422-9b54-f, Tilburg University, School of Economics and Management.
   6. Nasuh C. Buyukkaramikli & Peter Wigfield & Men Thi Hoang, 2021. "A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 51-73, February.
   7. Vogler, Sabine & Paris, Valérie & Ferrario, Alessandra & Wirtz, Veronika J. & Joncheere, Kees de & Schneider, Peter & Pedersen, Hanne Bak & Dedet, Guillaume & Babar, Zaheer-Ud-Din, 2017. "How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries," LSE Research Online Documents on Economics 68862, London School of Economics and Political Science, LSE Library.
   8. Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Discussion Paper 2020-023, Tilburg University, Center for Economic Research.
      • Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Discussion Paper 2020-023, Tilburg University, Tilburg Law and Economic Center.
   9. Alice M. Ellyson & Anirban Basu, 2021. "Do pharmaceutical prices rise anticipating branded competition?," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1070-1081, May.
   10. Seidu Dauda & Abe C. Dunn & Anne E. Hall, 2019. "Are Medical Care Prices Still Declining? A Systematic Examination of Quality-Adjusted Price Index Alternatives for Medical Care," BEA Working Papers 0166, Bureau of Economic Analysis.
   11. Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Other publications TiSEM eda6a1de-4db6-49a6-87e4-3, Tilburg University, School of Economics and Management.
   12. Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson, 2018. "How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations," American Journal of Health Economics, MIT Press, vol. 4(4), pages 433-453, Fall.
       • Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson, 2016. "How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations," NBER Working Papers 22986, National Bureau of Economic Research, Inc.
       • Kristopher J. Hult & Sonia Jaffe & Tomas J. Philipson, 2018. "How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations," American Journal of Health Economics, University of Chicago Press, vol. 4(4), pages 433-453, Fall.
   13. Jing Zhou & Tianjiao Lan & Hao Lu & Jay Pan, 2024. "Price negotiation and pricing of anticancer drugs in China: An observational study," PLOS Medicine, Public Library of Science, vol. 21(1), pages 1-18, January.
   14. Dauda, Seidu & Dunn, Abe & Hall, Anne, 2022. "A systematic examination of quality-adjusted price index alternatives for medical care using claims data," Journal of Health Economics, Elsevier, vol. 85(C).
   15. Chatterjee, Chirantan & Gupta, Samarth, 2024. "Public entry and private prices: New evidence from Indian pharmaceutical markets," Journal of Economic Behavior & Organization, Elsevier, vol. 219(C), pages 473-489.
   16. Salas-Vega, Sebastian & Shearer, Emily & Mossialos, Elias, 2020. "Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US," Social Science & Medicine, Elsevier, vol. 258(C).
   17. Caroline Savage Bennette & Anirban Basu & Scott D. Ramsey & Zachary Helms & Peter B. Bach, 2019. "Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion," American Journal of Health Economics, MIT Press, vol. 5(3), pages 360-375, Summer.
   18. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
   19. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
       • Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Post-Print hal-01571937, HAL.
   20. Seabury Seth A. & Goldman Dana P. & Gupta Charu N. & Khan Zeba M. & Chandra Amitabh & Philipson Tomas J. & Lakdawalla Darius N., 2016. "Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection," Forum for Health Economics & Policy, De Gruyter, vol. 19(1), pages 141-156, June.
   21. David B. Ridley & Chung-Ying Lee, 2020. "Does Medicare Reimbursement Drive Up Drug Launch Prices?," The Review of Economics and Statistics, MIT Press, vol. 102(5), pages 980-993, December.
   22. Perry, Teresa & Bernasek, Alexandra, 2024. "Profits over care? An analysis of the relationship between corporate capitalism in the healthcare industry and cancer mortality in the United States," Social Science & Medicine, Elsevier, vol. 349(C).
   23. Geng, Difei & Saggi, Kamal, 2020. "Optimal price regulations in international pharmaceutical markets with generic competition," Journal of Health Economics, Elsevier, vol. 71(C).
   24. Lucarelli, Claudio & Nicholson, Sean & Tilipman, Nicholas, 2022. "Price Indices and the Value of Innovation with Heterogenous Patients," Journal of Health Economics, Elsevier, vol. 84(C).
   25. Stefano Capri, 2020. "High prices of new drugs: we are ready to do whatever it takes," LIUC Papers in Economics 2020-8, Cattaneo University (LIUC).
   26. Dubois, Pierre & Kyle, Margaret, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality Rates," TSE Working Papers 16-688, Toulouse School of Economics (TSE).
   27. Boone, Jan, 2024. "Pricing above value: Selling to a market with selection problems," Journal of Health Economics, Elsevier, vol. 94(C).
   28. David Besanko & David Dranove & Craig Garthwaite, 2016. "Insurance and the High Prices of Pharmaceuticals," NBER Working Papers 22353, National Bureau of Economic Research, Inc.
   29. Tomás Rau & Miguel Sarzosa & Sergio S. Urzúa, 2017. "The Children of the Missed Pill," NBER Working Papers 23911, National Bureau of Economic Research, Inc.
       • Rau, Tomás & Sarzosa, Miguel & Urzúa, Sergio, 2021. "The children of the missed pill," Journal of Health Economics, Elsevier, vol. 79(C).
   30. Ivan Lugovoi & Dimitrios A. Andritsos & Claire Senot, 2022. "Novelty and scope of process innovation: The role of related and unrelated manufacturing experience," Production and Operations Management, Production and Operations Management Society, vol. 31(10), pages 3877-3895, October.
   31. Dankó, D. & Blay, J-Y. & Garrison, L.P., 2019. "Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology," Health Policy, Elsevier, vol. 123(12), pages 1230-1236.
   32. Gandjour, Afschin, 2022. "The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany," The Quarterly Review of Economics and Finance, Elsevier, vol. 84(C), pages 502-509.
   33. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
   34. Sylvain Chassang & Valentina Mantua & Erik Snowberg & Entela Xoxi & Luca Pani, 2018. "Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties," CESifo Working Paper Series 6846, CESifo.
   35. Radion Svynarenko & Qun Zhang & Hyungsoo Kim, 2019. "The Financial Burden of Cancer: Financial Ratio Analysis," Journal of Family and Economic Issues, Springer, vol. 40(2), pages 165-179, June.
   36. Anne E. Hall, 2015. "Adjusting the Measurement of the Output of the Medical Sector for Quality: A Review of the Literature," BEA Working Papers 0122, Bureau of Economic Analysis.
   37. Boone, Jan, 2020. "Pricing above value: selling to an adverse selection market," CEPR Discussion Papers 15279, C.E.P.R. Discussion Papers.
   38. Abe Dunn & Anne Hall & Seidu Dauda, 2022. "Are Medical Care Prices Still Declining? A Re‐Examination Based on Cost‐Effectiveness Studies," Econometrica, Econometric Society, vol. 90(2), pages 859-886, March.

9. Rena M. Conti & Ernst R. Berndt, 2014. "Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007," NBER Working Papers 20016, National Bureau of Economic Research, Inc.
   • Rena M. Conti & Ernst R. Berndt, 2016. "Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007," NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 273-321, National Bureau of Economic Research, Inc.

   Cited by:

   1. William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson, 2020. "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US," PharmacoEconomics, Springer, vol. 38(10), pages 1115-1121, October.
   2. Andrea Berlanda & Matteo Cervellati & Elena Esposito & Dominic Rohner & Uwe Sunde, 2022. "Medication Against Conflict," HiCN Working Papers 367, Households in Conflict Network.
      • Berlanda, Andrea & Cervellati, Matteo & Esposito, Elena & Rohner, Dominic & Sunde, Uwe, 2024. "Medication against conflict," Journal of Development Economics, Elsevier, vol. 170(C).
      • Andrea Berlanda & Matteo Cervellati & Elena Esposito & Dominic Rohner & Uwe Sunde, 2022. "Medication against Conflict," CESifo Working Paper Series 9650, CESifo.
      • Berlanda, Andrea & Cervellati, Matteo & Esposito, Elena & Rohner, Dominic & Sunde, Uwe, 2022. "Medication Against Conflict," CEPR Discussion Papers 17125, C.E.P.R. Discussion Papers.
   3. Jennie McKenney & Anders Chen & Karen W Hoover & Jane Kelly & David Dowdy & Parastu Sharifi & Patrick S Sullivan & Eli S Rosenberg, 2017. "Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men," PLOS ONE, Public Library of Science, vol. 12(6), pages 1-13, June.
   4. Ernst R. Berndt & Rena M. Conti & Stephen J. Murphy, 2017. "The Landscape of US Generic Prescription Drug Markets, 2004-2016," NBER Working Papers 23640, National Bureau of Economic Research, Inc.
   5. Liang Xu & Vidya Mani & Hui Zhao, 2023. "“Not a box of nuts and bolts”: Distribution channels for specialty drugs," Production and Operations Management, Production and Operations Management Society, vol. 32(7), pages 2283-2303, July.
   6. R. Brett McQueen & Kelly E. Anderson & Joseph F. Levy & Josh J. Carlson, 2023. "Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?," PharmacoEconomics, Springer, vol. 41(3), pages 321-327, March.
   7. Michael D. Frakes & Melissa F. Wasserman, 2020. "Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination," NBER Working Papers 27579, National Bureau of Economic Research, Inc.
   8. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.

10. Rena M. Conti & Haiden A. Huskamp & Ernst R. Berndt, 2011. "The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts," NBER Working Papers 17528, National Bureau of Economic Research, Inc.

    Cited by:

    1. Lawler, Emily C. & Skira, Meghan M., 2022. "Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal," Journal of Health Economics, Elsevier, vol. 81(C).

11. Rena M. Conti & Ernst R. Berndt & Richard G. Frank, 2006. "Early Retirement and Public Disability Insurance Applications: Exploring the Impact of Depression," NBER Working Papers 12237, National Bureau of Economic Research, Inc.

    Cited by:

    1. Stefanie Behncke, 2009. "How Does Retirement Affect Health?," University of St. Gallen Department of Economics working paper series 2009 2009-13, Department of Economics, University of St. Gallen.
       • Behncke, Stefanie, 2009. "How Does Retirement Affect Health?," IZA Discussion Papers 4253, Institute of Labor Economics (IZA).
       • Behncke S, 2009. "How Does Retirement Affect Health?," Health, Econometrics and Data Group (HEDG) Working Papers 09/11, HEDG, c/o Department of Economics, University of York.
    2. Jürgen Maurer & Roger Klein & Francis Vella, 2011. "Subjective Health Assessments and Active Labor Market Participation of Older Men: Evidence from a Semiparametric Binary Choice Model with Nonadditive Correlated Individual-specific Effects," The Review of Economics and Statistics, MIT Press, vol. 93(3), pages 764-774, August.
       • Maurer, Jürgen & Klein, Roger & Vella, Francis, 2007. "Subjective Health Assessments and Active Labor Market Participation of Older Men: Evidence from a Semiparametric Binary Choice Model with Nonadditive Correlated Individual-Specific Effects," IZA Discussion Papers 3257, Institute of Labor Economics (IZA).
       • Jürgen Maurer & Roger Klein & Francis Vella, 2008. "Subjective Health Assessments and Active Labor Market Participation of Older Men: Evidence from a Semiparametric Binary Choice Model with Nonadditive Correlated Individualspecific Effects," MEA discussion paper series 08169, Munich Center for the Economics of Aging (MEA) at the Max Planck Institute for Social Law and Social Policy.
    3. Bui, Thi Mai Van & Stolpe, Michael, 2007. "The impact of new drug launches on the loss of labor from disease and injury: evidence from German panel data," Kiel Working Papers 1317, Kiel Institute for the World Economy (IfW Kiel).
    4. Van Bui & Michael Stolpe, 2010. "The impact of new drug launches on the loss of labor from disease and injury: evidence from German panel data," International Journal of Health Economics and Management, Springer, vol. 10(4), pages 315-346, December.
    5. Jason M. Fletcher, 2008. "Adolescent depression: diagnosis, treatment, and educational attainment," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1215-1235, November.
    6. Renna, F. & Thakur, Nidhi, 2010. "Direct and indirect effects of obesity on U.S. labor market outcomes of older working age adults," Social Science & Medicine, Elsevier, vol. 71(2), pages 405-413, July.
    7. Wang, Yang & Yang, Muzhe, 2013. "Crisis-induced depression, physical activity and dietary intake among young adults: Evidence from the 9/11 terrorist attacks," Economics & Human Biology, Elsevier, vol. 11(2), pages 206-220.

Articles

1. Rena M. Conti & Ernst R. Berndt, 2020. "Four Facts Concerning Competition in US Generic Prescription Drug Markets," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 27(1), pages 27-48, January.

   Cited by:

   1. Jun Li & Di (Andrew) Wu, 2022. "The Price Effect of Drug Price Ceilings: Intended and Unintended Consequences," Management Science, INFORMS, vol. 68(8), pages 5758-5777, August.
   2. Yixin (Iris) Wang & Jun Li & Ravi Anupindi, 2023. "Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach," Management Science, INFORMS, vol. 69(3), pages 1449-1467, March.

2. David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," Journal of Economic Perspectives, American Economic Association, vol. 29(1), pages 139-162, Winter.
   • David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
   See citations under working paper version above.
3. Rena Conti & David L. Veenstra & Katrina Armstrong & Lawrence J. Lesko & Scott D. Grosse, 2010. "Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities," Medical Decision Making, , vol. 30(3), pages 328-340, May.

   Cited by:

   1. Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
   2. Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
   3. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
   4. Kerr, Anne & Hill, Rosemary L. & Till, Christopher, 2018. "The limits of responsible innovation: Exploring care, vulnerability and precision medicine," Technology in Society, Elsevier, vol. 52(C), pages 24-31.

Chapters

1. Rena M. Conti & Ernst R. Berndt, 2016. "Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007," NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 273-321, National Bureau of Economic Research, Inc.
   • Rena M. Conti & Ernst R. Berndt, 2014. "Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007," NBER Working Papers 20016, National Bureau of Economic Research, Inc.
   See citations under working paper version above.Sorry, no citations of chapters recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 11 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-COM: Industrial Competition (8) 2011-10-22 2014-04-05 2015-01-31 2017-08-06 2017-08-13 2019-10-07 2019-12-16 2021-06-28. Author is listed
2. NEP-HEA: Health Economics (8) 2011-10-22 2014-04-05 2015-01-31 2017-08-06 2017-08-13 2020-11-16 2021-04-19 2021-06-28. Author is listed
3. NEP-IND: Industrial Organization (3) 2014-04-05 2019-10-07 2019-12-16
4. NEP-BEC: Business Economics (1) 2011-10-22
5. NEP-CIS: Confederation of Independent States (1) 2011-10-22
6. NEP-CWA: Central and Western Asia (1) 2021-04-19
7. NEP-IAS: Insurance Economics (1) 2006-05-20
8. NEP-IPR: Intellectual Property Rights (1) 2014-04-05
9. NEP-LAW: Law and Economics (1) 2019-12-16
10. NEP-MKT: Marketing (1) 2011-10-22

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Rena Conti should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.